Skip to main content

30.04.2024 | Editorial

EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours

verfasst von: Donatienne Van Weehaeghe, Bruno Lapauw, Francesco Fraioli, Diego Cecchin, Antoine Verger, Eric Guedj, Nathalie L Albert, Matthias Brendel, Igor Yakushev, Henryk Barthel, Tatjana Traub-Weidinger, Nelleke Tolboom, Elsmarieke Van De Giessen

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Excerpt

Pituitary neuroendocrine tumours (PitNET) [1] are, after meningioma, the most frequent intracranial tumours. They are classified according to their size (micro < 10 mm, macro ≥ 10 mm and giant ≥ 40 mm), their hormonal secretion pattern and molecular expression profile. Although most PitNET are benign, they can cause significant morbidity due to local compression and associated hormonal syndromes. Clinical management is multidisciplinary, and treatment consists of surgical resection, radiotherapy, pharmacotherapy or a combination. Magnetic resonance imaging (MRI) is the primary diagnostic method, and dedicated protocols include dynamic contrast-enhanced imaging [2]. Ultra-high field MRI (7T) has shown to increase detection, particularly in small micro-PitNET [3]. However, there remain some unmet diagnostic needs. Some functional micro-PitNET (including 30–40% of corticotroph adenomas) are not readily visualized on standard pituitary MRI even when including a dynamic contrast enhanced sequences [4]. Further, even in patients with Cushing’s disease who have a micro-PitNET detected on MRI, guidelines suggest to confirm localization of the tumour within the pituitary gland through bilateral inferior petrosal sinus sampling (IPSS) [5]. This technique is considered the gold standard to confirm origin of adrenocorticotrope hormone hypersecretion. However, this invasive procedure has a risk of non-negligible complications and even neurologic damage. Similarly, following transsphenoidal surgery, sites of residual or recurrent disease may not be evident or readily distinguished from posttreatment changes [6], complicating redo surgery or adjuvant radiotherapy. Therefore, despite advancements in MR imaging modalities, more accurate imaging methods providing further information on activity and localization would prove beneficial for patients. Also, from another perspective, evaluation of metabolic characteristics of pituitary neuroendocrine tumours has potential to advance diagnostics. For instance, hormonal functionality of a pituitary incidentaloma is not always easy to confirm and MRI-based imaging provides primarily structural information, but little functional information, e.g. prognostic information on growth potential of the tumour. As, such molecular imaging could be of complementary value. …
Literatur
1.
Zurück zum Zitat Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol. 2022;33:6–26.CrossRefPubMed Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO classification of Pituitary tumors. Endocr Pathol. 2022;33:6–26.CrossRefPubMed
2.
Zurück zum Zitat Molitch ME. Diagnosis and treatment of Pituitary adenomas: a review. JAMA. 2017;317:516–24.CrossRefPubMed Molitch ME. Diagnosis and treatment of Pituitary adenomas: a review. JAMA. 2017;317:516–24.CrossRefPubMed
3.
Zurück zum Zitat de Rotte AAJ, Groenewegen A, Rutgers DR, Witkamp T, Zelissen PMJ, Meijer FJA, et al. High resolution pituitary gland MRI at 7.0 tesla: a clinical evaluation in Cushing’s disease. Eur Radiol. 2016;26:271–7.CrossRefPubMed de Rotte AAJ, Groenewegen A, Rutgers DR, Witkamp T, Zelissen PMJ, Meijer FJA, et al. High resolution pituitary gland MRI at 7.0 tesla: a clinical evaluation in Cushing’s disease. Eur Radiol. 2016;26:271–7.CrossRefPubMed
4.
Zurück zum Zitat Erickson D, Erickson B, Watson R, Patton A, Atkinson J, Meyer F, et al. 3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing’s syndrome. Clin Endocrinol (Oxf). 2010;72:793–9.CrossRefPubMed Erickson D, Erickson B, Watson R, Patton A, Atkinson J, Meyer F, et al. 3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing’s syndrome. Clin Endocrinol (Oxf). 2010;72:793–9.CrossRefPubMed
5.
Zurück zum Zitat Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847–75.CrossRefPubMedPubMedCentral Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847–75.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat MacFarlane J, Bashari WA, Senanayake R, Gillett D, van der Meulen M, Powlson AS, et al. Advances in the imaging of Pituitary tumors. Endocrinol Metab Clin North Am. 2020;49:357–73.CrossRefPubMed MacFarlane J, Bashari WA, Senanayake R, Gillett D, van der Meulen M, Powlson AS, et al. Advances in the imaging of Pituitary tumors. Endocrinol Metab Clin North Am. 2020;49:357–73.CrossRefPubMed
7.
Zurück zum Zitat Iglesias P, Cardona J, Díez JJ. The pituitary in nuclear medicine imaging. Eur J Intern Med. 2019;68:6–12.CrossRefPubMed Iglesias P, Cardona J, Díez JJ. The pituitary in nuclear medicine imaging. Eur J Intern Med. 2019;68:6–12.CrossRefPubMed
8.
Zurück zum Zitat Tjörnstrand A, Casar-Borota O, Heurling K, Schöll M, Gjertsson P, Ragnarsson O, et al. Pre- and postoperative 68 Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumours. Clin Endocrinol (Oxf). 2021;94:956–67.CrossRefPubMed Tjörnstrand A, Casar-Borota O, Heurling K, Schöll M, Gjertsson P, Ragnarsson O, et al. Pre- and postoperative 68 Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumours. Clin Endocrinol (Oxf). 2021;94:956–67.CrossRefPubMed
9.
Zurück zum Zitat Novruzov F, Aliyev A, Wan MYS, Syed R, Mehdi E, Aliyeva I, et al. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. 2021;5:10.CrossRefPubMedPubMedCentral Novruzov F, Aliyev A, Wan MYS, Syed R, Mehdi E, Aliyeva I, et al. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors. Eur J Hybrid Imaging. 2021;5:10.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Gillett D, MacFarlane J, Bashari W, Crawford R, Harper I, Mendichovszky IA, et al. Molecular Imaging of Pituitary tumors. Semin Nucl Med. 2023;53:530–8.CrossRefPubMed Gillett D, MacFarlane J, Bashari W, Crawford R, Harper I, Mendichovszky IA, et al. Molecular Imaging of Pituitary tumors. Semin Nucl Med. 2023;53:530–8.CrossRefPubMed
11.
Zurück zum Zitat Bauman MMJ, Graves JP, Harrison DJ, Hassett LC, Bancos I, Johnson DR, et al. The utility of PET for detecting corticotropinomas in Cushing disease: a scoping review. Neurosurg Rev. 2023;46:160.CrossRef Bauman MMJ, Graves JP, Harrison DJ, Hassett LC, Bancos I, Johnson DR, et al. The utility of PET for detecting corticotropinomas in Cushing disease: a scoping review. Neurosurg Rev. 2023;46:160.CrossRef
12.
Zurück zum Zitat Koulouri O, Hoole AC, English P, Allinson K, Antoun N, Cheow H, et al. Localisation of an occult thyrotropinoma with 11 C-methionine PET-CT before and after somatostatin analogue therapy. Lancet Diabetes Endocrinol. 2016;4:1050.CrossRefPubMed Koulouri O, Hoole AC, English P, Allinson K, Antoun N, Cheow H, et al. Localisation of an occult thyrotropinoma with 11 C-methionine PET-CT before and after somatostatin analogue therapy. Lancet Diabetes Endocrinol. 2016;4:1050.CrossRefPubMed
13.
Zurück zum Zitat Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS, et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11 C-methionine PET co-registered with MRI. Eur J Endocrinol. 2016;175:485–98.CrossRefPubMed Koulouri O, Kandasamy N, Hoole AC, Gillett D, Heard S, Powlson AS, et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11 C-methionine PET co-registered with MRI. Eur J Endocrinol. 2016;175:485–98.CrossRefPubMed
14.
Zurück zum Zitat Bakker LEH, Verstegen MJT, Ghariq E, Verbist BM, Schutte PJ, Bashari WA, et al. Implementation of functional imaging using 11 C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary. 2022;25:587–601.CrossRefPubMedPubMedCentral Bakker LEH, Verstegen MJT, Ghariq E, Verbist BM, Schutte PJ, Bashari WA, et al. Implementation of functional imaging using 11 C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary. 2022;25:587–601.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Pruis IJ, Verburg FA, Balvers RK, Harteveld AA, Feelders RA, Vernooij MW et al. [ 18 F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors. Journal of Nuclear Medicine. 2024;jnumed.123.266853. Pruis IJ, Verburg FA, Balvers RK, Harteveld AA, Feelders RA, Vernooij MW et al. [ 18 F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors. Journal of Nuclear Medicine. 2024;jnumed.123.266853.
16.
Zurück zum Zitat Heimburger C, Bund C, Addeo P, Goichot B, Imperiale A. 18F-FDOPA uptake reflects the efficacy of dopamine agonists treatment in Pituitary Prolactinoma. Clin Nucl Med. 2018;43:e324–5.CrossRefPubMed Heimburger C, Bund C, Addeo P, Goichot B, Imperiale A. 18F-FDOPA uptake reflects the efficacy of dopamine agonists treatment in Pituitary Prolactinoma. Clin Nucl Med. 2018;43:e324–5.CrossRefPubMed
17.
Zurück zum Zitat Ginet M, Cuny T, Schmitt E, Marie P-Y, Verger A. 18F-FDOPA PET imaging in Prolactinoma. Clin Nucl Med. 2017;42:e383–4.CrossRefPubMed Ginet M, Cuny T, Schmitt E, Marie P-Y, Verger A. 18F-FDOPA PET imaging in Prolactinoma. Clin Nucl Med. 2017;42:e383–4.CrossRefPubMed
18.
Zurück zum Zitat Slagboom TNA, Stenvers DJ, van de Giessen E, Roosendaal SD, de Win MML, Bot JCJ et al. Continuing challenges in the definitive diagnosis of Cushing’s Disease: a structured review focusing on Molecular Imaging and a proposal for Diagnostic Work-Up. J Clin Med. 2023;12. Slagboom TNA, Stenvers DJ, van de Giessen E, Roosendaal SD, de Win MML, Bot JCJ et al. Continuing challenges in the definitive diagnosis of Cushing’s Disease: a structured review focusing on Molecular Imaging and a proposal for Diagnostic Work-Up. J Clin Med. 2023;12.
19.
Zurück zum Zitat Muhr C. Positron Emission Tomography in Acromegaly and other Pituitary Adenoma patients. Neuroendocrinology. 2006;83:205–10.CrossRefPubMed Muhr C. Positron Emission Tomography in Acromegaly and other Pituitary Adenoma patients. Neuroendocrinology. 2006;83:205–10.CrossRefPubMed
20.
Zurück zum Zitat Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M. Clinical usefulness of Coregistered 11 C-Methionine Positron Emission Tomography/3-T magnetic resonance imaging at the Follow-Up of Acromegaly. World Neurosurg. 2014;82:468–73.CrossRefPubMed Rodriguez-Barcelo S, Gutierrez-Cardo A, Dominguez-Paez M, Medina-Imbroda J, Romero-Moreno L, Arraez-Sanchez M. Clinical usefulness of Coregistered 11 C-Methionine Positron Emission Tomography/3-T magnetic resonance imaging at the Follow-Up of Acromegaly. World Neurosurg. 2014;82:468–73.CrossRefPubMed
21.
Zurück zum Zitat Bashari WA, Senanayake R, Koulouri O, Gillett D, MacFarlane J, Powlson AS, et al. PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus. 2020;48:E8.CrossRefPubMed Bashari WA, Senanayake R, Koulouri O, Gillett D, MacFarlane J, Powlson AS, et al. PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly. Neurosurg Focus. 2020;48:E8.CrossRefPubMed
22.
Zurück zum Zitat Quinn M, Bashari W, Smith D, Gurnell M, Agha A. A remarkable case of thyrotoxicosis initially caused by graves’ disease followed by a probable TSHoma - a case report. BMC Endocr Disord. 2020;20:133.CrossRefPubMedPubMedCentral Quinn M, Bashari W, Smith D, Gurnell M, Agha A. A remarkable case of thyrotoxicosis initially caused by graves’ disease followed by a probable TSHoma - a case report. BMC Endocr Disord. 2020;20:133.CrossRefPubMedPubMedCentral
Metadaten
Titel
EANM position on positron emission tomography in suspected functional pituitary neuroendocrine tumours
verfasst von
Donatienne Van Weehaeghe
Bruno Lapauw
Francesco Fraioli
Diego Cecchin
Antoine Verger
Eric Guedj
Nathalie L Albert
Matthias Brendel
Igor Yakushev
Henryk Barthel
Tatjana Traub-Weidinger
Nelleke Tolboom
Elsmarieke Van De Giessen
Publikationsdatum
30.04.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-024-06728-4